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The effect of warfarin therapy on endoleak
development after endovascular aneurysm repair
(EVAR) of the abdominal aorta
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Objectives: The presence of an endoleak after endovascular abdominal aortic aneurysm (AAA) repair (EVAR) may predispose
to sac expansion and potential sac rupture. The incidence of endoleak after AAA repair can be as high as 20% to 30%. We
investigated whether warfarin anticoagulation was an independent risk factor for endoleak after EVAR for AAA.
Methods:All AAA patients who underwent elective EVARwere prospectively followed-up. Data for demographics, clinical
comorbidities, outcomes, EVAR devices, and anticoagulation methods were recorded. All patients underwent routine
follow-up at 1, 6, and 12 months and annually thereafter. Computed tomography angiography (CTA) with 3-dimensional
(3D) volumetric analysis was also completed.
Results: During a 7-year period, 127 consecutive patients with infrarenal AAAs who underwent EVAR were monitored
for a mean of 2.14 years. The average age at the time of EVAR was 73.8 years. Warfarin therapy alone was administered
to 24 patients, and anticoagulation with antiplatelet therapy alone was administered to 103. During the study period, 38
(29.9%) endoleaks were documented. The overall endoleak rate was 13 of 24 in the warfarin group and 25 of 103 in the
antiplatelet group (P  .004). CTA 3D volumetric aneurysm sac analysis showed an increase of 16.09% in the warfarin
study group and a reduction of 9.71% in the antiplatelet group (P  .04).
Conclusions:Anticoagulation with warfarin appears to be linked to an increased risk for the development of endoleak after
EVAR, specifically type II. Volumetric analysis showed warfarin therapy also contributed to persistent aneurysm sac
expansion. These data suggest that patients who require warfarin anticoagulation for other indications should be advised
that they might be at an increased risk for the development of endoleaks, subsequent secondary interventions, persistent
sac expansion, and possible delayed sac rupture. ( J Vasc Surg 2010;52:267-71.)Each year, 200,000 abdominal aortic aneurysms
(AAAs) are diagnosed in the United States alone, and
15,000 aneurysms reach the size criterion for repair.1,2
The peak incidence of diagnosis is in men aged 65 to 75
years. With the recent approval for Medicare-sanctioned,
one-time, entry AAA ultrasound screening in men qualify-
ing by the US Preventive Services Task Force guideline
recommendations, an increase in the number of patients
with AAAs requiring monitoring and repair is anticipated.2
Although traditional open AAA repair is safe and effec-
tive in the elective setting, endovascular aneurysm repair
(EVAR) for AAAs has gained significant popularity due to
the growing complexity of patients’ comorbid conditions,
the need to provide cost-effective care, and the push toward
minimally invasive and endoluminal therapies. The primary
aim of EVAR is to exclude flow from the sac while main-
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precisely defined as:
“ . . . a condition associated with endoluminal vascular
grafts, defined by the persistence of blood flow outside
the lumen of the endoluminal graft, but within an aneu-
rysm sac or adjacent vascular segment being treated by the
graft . . . .”3
Endoleaks are classified as type I through type IV.3,4
There have been conflicting data about whether AAA pa-
tients who require warfarin therapy after EVAR are predis-
posed to the development of endoleaks5-7 as well as for the
risk factors for endoleak development in general.8-12 The
purpose of this study was to determine if warfarin therapy
was associated with increased risk for endoleak, specifically
type II, after EVAR in our endoluminal experience.
METHODS
During a 7-year contiguous period from January 1,
2000, to January 31, 2007, all patients with an AAA who
underwent EVARwere prospectively enrolled into a clinical
database. Data for demographics, clinical comorbidities,
outcomes, EVAR devices, and anticoagulation methods
were recorded prospectively in a clinical database. All pa-
tients underwent routine follow-up at 1, 6, and 12 months
and annually thereafter, which included computed tomog-
raphy angiography (CTA) with 3-dimensional (3D) volu-
metric analysis. We then completed a retrospective review
of the collected data to determine if warfarin therapy in-
creased endoleak rates in these patients.
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helical imaging through the abdomen and pelvis, followed
by contrast-enhanced 1.25-mm helical images acquired
during the arterial phase of contrast enhancement and
delayed 5-mm helical images. Scanning parameters were
kept as consistent as possible: 120 kV; smart/automatic
tube current range of 80 to 750 mA or 80 to 440 mA;
noise index, 16; section thickness/reconstruction interval,
1.25 mm/0.75 mm; pitch, 0.516:1 to 0.625:1; interval,
0.75 mm; and rotation time, 500 msec. For the arterial
phase, 150 mL of intravenous contrast material (iohexol
[iodine, 300 mg/mL], Omnipaque 300, GE Healthcare,
Princeton, NJ), and subsequently, a 50-mL saline chaser
bolus, were injected through an antecubital vein at 5mL/s.
Arterial-phase scanning was performed by using automatic
scan start with a 6-second diagnostic delay after crossing
the threshold attenuation (100 HU). Late-phase images
were acquired 70 seconds after injection of the contrast
material.
The 3D reconstruction included segmentation of the
aneurysm sac, and the sac volume was calculated using a
workstation (Volume Viewer 2 Advantage, GEHealthcare,
Waukesha, Wisc). Source images were evaluated for the
presence of endoleak by an experienced cardiovascular ra-
diologist. The 3D and multiplanar reconstructions, as well
as volume measurements, were evaluated to determine
aneurysm configuration and volumetric changes over
time.13
Patients were analyzed for endoleak stratified by anti-
coagulation method. Subgroups consisted of antiplatelet
therapy alone (aspirin or clopidogrel) and warfarin alone.
Type I thru IV endoleaks were classified by published
guidelines. Predefined end points of the study included
time to endoleak, persistent endoleak requiring reinterven-
tion, and aneurysm sac volumetric expansion. Rank-sum
and t-test analyses were used to assess risk factors and other
patient characteristic differences. A value of P  .05 was
considered statistically significant in all analyses.
RESULTS
During a 7-year period from January 2000 to January
2007, 127 consecutive patients (14 women, 113men) with
AAAs underwent EVAR at the University of Wisconsin–
Madison. All aneurysms were infrarenal in nature and were
a mean size of 5.9  12 cm at repair. At the time of repair,
patients were a mean age of 73.8  8.3 years and had a
mean body mass index (BMI) of 28.3  6.9 kg/m2.
Of the 127 patients, 103 were treated with antiplatelet
agents alone (aspirin or clopidogrel). Twenty-four patients
required warfarin therapy for atrial fibrillation and other
cardiovascular comorbidities before EVAR and continued
receiving warfarin therapy during the study. The goal in-
ternational normalized ratio (INR) therapeutic target was
2.0 to 3.0 in all patients. Mean follow-up was 2.14 years.
We attempted to identify outcome-specific differences
based on the anticoagulation regimen in our study popula-
tion. There were no significant differences in age (P .37),
gender (P .99), aneurysm size (P .80), BMI (P .36),American Society of Anesthesiologists’ (ASA) score (P 
.28), endograft type (P  .48), or average length of
follow-up (P  .38) between the antiplatelet and warfarin
groups (Table I). The incidence of coronary arterial disease
(CAD) was higher in the warfarin group (91.7% vs 62.1%,
P  .006); however, all other comorbidities were equal
between the groups (Table I).
The incidence of endoleak significantly increased in the
warfarin group (P  .004). A total of 38 endoleaks were
documented during the course of this study, including 8
type I, 28 type II, 1 type III, and 1 type IV; of which 13
occurred in the warfarin group (n 24) and 25 occurred in
the antiplatelet group (n  103). Type II endoleak was
significantly more common in the warfarin group (P 
.02). Clinical progression was documented in nine type II
endoleaks associated with warfarin therapy, with sac vol-
umes increasing an average of 46.8 cm3 compared with the
mean sac volume change of –3.1 cm3 in the 19 antiplatelet-
related type II leaks. Of these type II endoleaks, 4 of 9
(44%) in the warfarin group resolved without secondary
intervention, whereas 9 of 19 (47%) in the antiplatelet
group resolved similarly. There was no significant differ-
ence in the overall mean time to the first detection of
endoleak between the two groups (201 days antiplatelet,
Table I. Demographic and risk factor analysesa
Category
Antiplatelet
group
(n  103)
Warfarin
group
(n  24) P value
Gender,b No. .99
Male 91 22
Female 12 2
Age,c years 74.1  8.3 72.3  8.5 .37
Aneurysm size,c cm 5.77  1.2 6.34  1.2 .80
BMI,c kg/m2 28.1  6.8 29.5  7.5 .36
ASA scorec 3.09  0.5 3.28  0.5 .28
Comorbidities,b No. (%)
None 9 (8.7) 0 (0) .21
CAD 64 (62.1) 22 (91.7) .006
COPD 36 (35.0) 6 (25.0) .47
Diabetes mellitus 18 (17.5) 8 (33.3) .096
Hypertension 68 (66.0) 17 (70.8) 0.81
Endograft type,b No. 0.48
Ancured 23 4
AneuRxe 33 8
Zenithf 15 3
Excluderg 32 8
UniGraft KDVh 0 1
Follow-up,c days 743.5 948.3 0.38
ASA, American Society of Anesthesiologists; BMI, body mass index; CAD,
coronary artery disease; COPD, chronic obstructive pulmonary disease.
aOverall, there were no significant differences between the antiplatelet group
and warfarin group. Five endovascular devices were used during the study.
bRisk factor comparison by Fisher exact test.
cRisk factor comparison by Wilcoxon rank-sum analysis.
dGuidant, Endovascular Solutions, Melo Park, Calif.
eMedtronic, AVE, Santa Rosa, Calif.
fCook Medical Inc, Bloomington, Ind.
gW. L. Gore and Assoc., Flagstaff, Ariz.
hGuidant Endovascular Systems.158 days warfarin; P  .40).
s patie
c pres
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differences in initial aneurysm sac volumes based on preop-
erative studies (195.11 cm3 antiplatelet, 181.84 cm3 war-
farin; P  .4). At the conclusion of the study, however,
mean sac volume in the warfarin group had significantly
increased to 213.34 cm3 compared with a mean decrease in
the antiplatelet group to 174.34 cm3. This marked an
overall aneurysm sac volume increase of 16.09% (29.3 cm3)
in the warfarin study group compared with a reduction of
9.71% (18.9 cm3) in the antiplatelet group (P .04). This
disparity was most evident in the proven endoleak groups,
with an average change of 38.5 cm3 in the warfarin
endoleak-positive group compared with –8.9 cm3 in the
antiplatelet endoleak-positive group (P  .04). A similar
although not statistically significant trend was seen in those
patients without a proven endoleak (warfarin endoleak-
negative group, 6.2 cm3; antiplatelet endoleak-negative
group, –23.5 cm3; P  .14).
There were 14 repeat interventions during the course
of this study: 8 of 25 (32%) in the antiplatelet group
required repeat intervention vs 6 of 13 (46%) in the warfa-
rin group, with endoleak-specific reinterventions in 7 and
6, respectively (P .03; Tables II and III). There were five
endograft explantations with conversion to open repair,
three in the warfarin group and two in the antiplatelet
group. All three in the warfarin group were for continued
aneurysm sac expansion despite reintervention. The two in
the antiplatelet group were for delayed rupture and infec-
tion. One patient in the antiplatelet group with a known
type II endoleak refused reintervention and died of delayed
Table II. Endovascular aneurysm repair outcomesa
Category
Antipla
(n 
Time to endoleak detection,b days (range) 142 (
Endoleaks,c No. (%) 25
Leak typec
I 5
II 19
III 1
IVd 0
Initial volume,b cm3 195.1
Final volume,b cm3 174.3
Volume change,b cm3 (%) 18.9
Repeat interventions,c No. (%) 8
EVAR explantations, No.
Continued expansion 0
Delayed rupture w/explant 1
Infected graft 1
Overall survival,b days (range) 968.6 
NA, Not applicable.
aWarfarin therapy was associated with a significant increase in endoleak fo
angiography showed increased aneurysm sac volumes despite endovascular
bParameter comparison by Wilcoxon rank-sum analysis.
cParameter comparison by Fisher exact test.
dThe type IV endoleak was experienced with a first-generation device. Thi
angiography evidence of a type I-III endoleak; at explantation, the mean saaneurysm sac rupture.DISCUSSION
EVAR has provided an alternative to traditional open
repair that is associated with less perioperative risk, de-
creased postoperative mortality, and shorter hospital
stays.1,14-17 This, however, comes with a tradeoff of a slight
increase in postoperative repair failure, increased need for
repeat intervention, and the endoluminal-exclusive compli-
cation of endoleak after EVAR.3,18
Endoleak predisposes to the risk of further aneurysm
sac expansion and, potentially, delayed sac rupture.3 There
have been conflicting data on the role of warfarin anticoag-
ulation in the pathogenesis of endoleak formation.5-7 Iyer
et al7 described the phenomenon of reversible endotension
during periods of excessive anticoagulation associated with
supratherapeutic INRwhile patients received warfarin ther-
apy.7 Others have observed decreased sac contracture after
EVAR in those patients requiring warfarin anticoagula-
tion.6 In this study, we aimed to investigate the role of
warfarin in endoleak formation and to monitor aneurysm
sac expansion by using 3D volumetric analysis.
We found that warfarin therapy was associated with an
increased endoleak incidence after EVAR, and together,
these were a major cause of continued AAA sac expansion
after EVAR. Interestingly, warfarin appeared to be associ-
ated with continued sac expansion regardless of endoleak
status, although the greatest sac expansion occurred in the
subset of patients who were endoleak-positive and receiv-
ing warfarin therapy. Those patients maintained on anti-
platelet agents alone continued to have sac shrinkage even if
they were endoleak-positive on average. These observa-
group
)
Warfarin group
(n  24) P value
77) 158 (31-728) .4
3) 13 (54.2) .004
.02
3
9
0
1
4.8 181.84  62.4 .4
4.5 213.34  113.9 .4
.71) 29.3 (16.09) .04
6 (46) .03
3 NA
0 NA
0 NA
2432) 1069.2  (55-1812) .8
n, predominantly type II. Volumetric analysis by computed tomography
sm repair.
nt demonstrated continued sac expansion without computed tomography
sure was 60 mm Hg with blunted pulsatility.telet
103
28-16
(24.
1  6
4  6
(9
(32)
(54-
rmatio
aneurytions would suggest that warfarin therapy alone may pre-
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cols, or may result in persistent sac endotension that results
in continued sac expansion.
This persistent sac expansion was not associated with an
increased risk for delayed rupture in our study, however.
This may be related to the small number of patients or to a
more aggressive strategy for dealing with progressing en-
doleaks in these patients. We did not find a link between a
specific EVAR device and persistent endoleak or continued
sac expansion.
Despite equal follow-up intervals, the 5-year cumula-
tive risk of endoleak nearly doubled when patients were
receiving warfarin therapy. The overall incidence of en-
doleak in our study was somewhat higher than the inci-
dence in previously published studies, although other
groups have reported similar rates, with 3-year reinterven-
tion rates as high as 35%.19 This may be partly due to an
aggressive CT screening protocol and a low threshold for
reintervention. Warfarin therapy appeared to be associated
with de novo late endoleak formation as well as with a
higher incidence of early endoleak identification.
Of all endoleaks, type II was the most common. Inter-
estingly, the resolution rate of early type II endoleaks did
not appear to be significantly affected (44% warfarin, 47%
antiplatelet), although an absolute increase in the numbers
of type II endoleak was observed. This observation may be
due to anticoagulant-driven failure of initial thrombosis of
collaterals or subsequent transient supratherapeutic levels
of anticoagulation leading to persistently patent collateral
vessels and reversible endotension. These collateral vessels
then feed the sac and prevent shrinkage, consistent with the
mean increase in sac volumes observed by CTA volumetric
Table III. I. Repeat interventionsa
Leak group Time to leak (days) Leak type
Antiplatelet
1 9 I
2 28 I
3 35 III
4 40 I
5 72 I
6 248 I
7 1556 Infected
8 1677 III
Warfarin
1 38 IV
2 38 II
3 99 II
4 321 I
5 636 II
6 728 I
IMA, Inferior mesenteric artery.
aMost reinterventions were for complications of endoleak. Patient 7 was
reintervention due to endoleak between the anticoagulation groups. Patie
emergency explantation.
bMedtronic, AVE, Santa Rosa, Calif.
cW. L. Gore and Assoc, Flagstaff, Ariz.
dGuidant Endovascular Solutions, Menlo Park, Calif.
eCook Medical Inc, Bloomington, Ind.analyses seen in our study.These results suggest patients who require warfarin
therapy after EVAR should be closely monitored for en-
doleak and that they are at risk for both early and late
endoleaks. Discontinuation of warfarin therapy, if clinically
possible, should be considered. When warfarin therapy
cannot be discontinued, patients should undergo monitor-
ing for persistent sac expansion. Alternatively, open repair
may be considered for patients who require life-long war-
farin anticoagulation to reduce cumulative radiation expo-
sure, subsequent repeat interventions, and the need long-
term surveillance.
CONCLUSIONS
Anticoagulation with warfarin appears to be linked to
an increased risk for the development of endoleak after
EVAR, specifically, type II endoleaks. Warfarin therapy also
contributed to persistent aneurysm sac expansion by volu-
metric analysis; however, this was not associated with an
increased risk of delayed sac rupture in our results. No
single risk factor, other than warfarin therapy, could be
identified that predisposed to endoleak formation. Our
study also suggested that those patients requiring warfarin
anticoagulation for other indications are at increased risk
for secondary interventions and are at risk for persistent sac
expansion. Close monitoring of AAA patients who require
warfarin therapy for other indications after EVAR is ad-
vised.
Anticoagulation with warfarin in the AAA patients who
have undergone EVAR is associated with an increase in the
incidence of type II endoleaks, aneurysm sac expansion,
and the rate of subsequent reintervention. Further study
Initial size (cm) Device Reinterventions
7.4 AneuRxb Extension cuff
5.1 Excluderc Extension cuff
7.0 AneuRx Stent graft
5.2 Ancured Extension cuff
7.0 AneuRx Extension cuff
6.5 AneuRx Extension cuff
5.5 Ancure Explanted
7.5 AneuRx Explanted
5.5 Zenithe Explanted
5.3 Excluder IMA coiling
5.5 Excluder IMA coiling
5.5 AneuRx Extension cuff
8.0 AneuRx Explanted
5.9 AneuRx Explanted
nted for infected endograft and was not used in the analysis comparing
as diagnosed with a type III endoleak at the time of delayed rupture andexpla
nt 8 wwith larger patient populations is warranted and necessary.
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